IMIM - Institut Hospital del Mar d'Investigacions Mèdiques


  • ADR Substantiation: Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due to the prominent implications to both public health and the pharmaceutical industry, it is of great importance to unravel the molecular mechanisms by which an adverse drug reaction can be potentially elicited. These mechanisms can be investigated by placing the pharmaco-epidemiologically detected adverse drug reaction in an information-rich context and by exploiting all currently available biomedical knowledge to substantiate it. We present a computational framework for the biological annotation of potential adverse drug reactions. The proposed framework seeks to provide a biological explanation (signal substantiation) by exploring mechanistic connections that might explain why a drug produces a specific adverse reaction. The mechanistic connections include the activity of the drug, related compounds and drug metabolites on protein targets, the association of protein targets to clinical events, and the annotation of proteins (both protein targets and proteins associated with clinical events) to biological pathways. Hence, the substantiation workflow (ADR-S workflow) integrates modules for in silico drug-target profiling, and analyses based on gene-disease networks and biological pathways. The ADR-S workflow offers a novel approach to explore the molecular mechanisms underlying adverse drug reactions.
  • Calculation of Cardiovascular risk: REGICOR researchers have developed in the network environment HERACLES an adaptation of the Framingham risk function, is now officially used by the National Health System of Catalonia, Basque Country and the Balearic Islands. Though the network us scheduled HERACLES HTML application that allows you to easily calculate and print the results with heart-healthy tips. 
  • DisGeNET is a plugin for Cytoscape to query and analyze a network representation of human gene-disease databases. For this purpose, we have developed a new gene-disease database integrating data from several public sources.
  • FCP: FCP is a publicly accessible web tool dedicated to analysing the current state and trends on the population of available structures along the classification schemes of enzymes (specially kinases and proteases), G protein-coupled receptors, nuclear receptors and transporters/channels, offering both graphical and quantitative data on the degree of functional coverage in that portion of the proteome by existing structures, as well as on the bias observed in the distribution of those structures among proteins.
  • GRANMO sample size calculation programme: New version of the well-known freeware GRANMO sample size calculation programme. This programme was developed over two decades ago by the URLEC Consortium, more specifically by the research groups at Cardiovascular Risk and Nutrition and Cardiovascular Epidemiology and Genetics of the Research Programme on Cardiovascular and Inflammatory Processes of the IMIM - Hospital del Mar, and since then the number of users has not stopped growing. More information
    • GRANMO ZIP: Programme for calculating sample size and the power of a contrast of hypothesis. April 2012.
    • GRANMO for Windows: Programme for calculating sample size and the power of a contrast of hypothesis. April 2012.
    • GRANMO online: Programme for calculating sample size and the power of a contrast of hypothesis. April 2012.
  • iPHACE: iPHACE is an integrative web-based tool to navigate in the pharmacological space defined by small molecule drugs contained in the IUPHAR-DB and PDSP databases. Extending beyond traditional querying and filtering tools, iPHACE offers a means to extract knowledge from the target profile of drugs as well as from the drug profile of protein targets.
  • PEAKS:The positional footprinting web server. PEAKS can be used to identify significant motif positional biases in DNA sequences.

© Institut Hospital del Mar d'Investigacions Mèdiques Legal Note | Cookie Policy | Site Index | Accessibility | Find Us | Contact